SCHEMBL405016

SCHEMBL405016

Cc1nc2c(Cl)nc3ccc(Cl)cc3c2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
TYMS P04818 1/20 0.48
PIM1 P11309 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
HTT P42858 1/20 0.39
MPO P05164 1/20 0.38
NPFFR1 Q9GZQ6 1/20 0.38
NPFFR2 Q9Y5X5 1/20 0.38
HSP90AB1 P08238 1/20 0.38
HTR3A P46098 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
PIM3 Q86V86 1/20 0.37
KDM4E B2RXH2 2/20 0.37
CSNK2A1 P68400 1/20 0.37
CHEK1 O14757 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL406115 0.76 PDE10A (0.49) ALDH1A1HTR3AHRH4KDM4EMEN1
SCHEMBL405432 0.76 HRH4 (0.57) ALDH1A1HTR3AHRH4KDM4EUSP2
SCHEMBL405945 0.73 PARP1 (0.49) ALDH1A1PIM1PIM2PIM3CSNK2A1
SCHEMBL31463101 0.72 TYMS (0.72) ALDH1A1TYMSPIM1PIM2HTR3A
SCHEMBL5313776 0.72 TYMS (0.72) ALDH1A1TYMSPIM1PIM2HTR3A
SCHEMBL30758201 0.71 ALDH1A1 (0.57) ALDH1A1TYMSPIM1PIM2HTT
SCHEMBL16415817 0.70 F7 (0.41) ALDH1A1KDM4ECHEK1
SCHEMBL10731553 0.70 KDM4E (0.43) ALDH1A1HTTMPONPFFR1NPFFR2
SCHEMBL404818 0.69 ALDH1A1 (0.41) ALDH1A1MPONPFFR1NPFFR2HSP90AB1
SCHEMBL1844868 0.68 PARP1 (0.46) ALDH1A1TYMSPIM1PIM2MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 ALDH1A1 1909/4885TYMS 1977/4885PIM1 4716/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 ALDH1A1 1909/4885TYMS 1977/4885PIM1 4716/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 ALDH1A1 1909/4885TYMS 1977/4885PIM1 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.